Who are Analgesic/antipyretic and antihistamine drugs's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/analgesic-antipyretic-and-antihistamine-drugs.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Analgesic/antipyretic and antihistamine drugs — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analgesic/antipyretic and antihistamine drugs (Analgesic/antipyretic and antihistamine drugs) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination analgesic/antipyretic and antihistamine. Area: Pain Management, Allergy/Immunology.

phase 3 Combination analgesic/antipyretic and antihistamine Pain Management, Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Analgesic/antipyretic and antihistamine drugs (Analgesic/antipyretic and antihistamine drugs) — Genentech, Inc.. This is a combination drug class that reduces pain and fever through analgesic/antipyretic action while simultaneously blocking histamine receptors to reduce allergic responses.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Analgesic/antipyretic and antihistamine drugs TARGET	Analgesic/antipyretic and antihistamine drugs	Genentech, Inc.	phase 3	Combination analgesic/antipyretic and antihistamine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination analgesic/antipyretic and antihistamine class)

Genentech, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Analgesic/antipyretic and antihistamine drugs — Competitive Intelligence Brief. https://druglandscape.com/ci/analgesic-antipyretic-and-antihistamine-drugs. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab